Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma

References

• Haynes BF, Bunn P, Mann D, et al. Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides. J Clin Invest 1981;67:523–530.
   PubMed Web of Science ®Google Scholar
• Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 1996;88:2385–2409.
   PubMed Web of Science ®Google Scholar
• Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ. Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma. J Am Acad Dermatol 2010;62:300–307.
   PubMed Web of Science ®Google Scholar
• Introcaso CE, Hess SD, Kamoun M, Ubriani R, Gelfand JM, Rook AH. Association of change in clinical status and change in the percentage of the CD4+CD26− lymphocyte population in patients with Sezary syndrome. J Am Acad Dermatol. 2005;53:428–434.
   PubMed Web of Science ®Google Scholar
• Vonderheid EC. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol 2006;33(Suppl. 1):27–42.
   PubMed Web of Science ®Google Scholar
• Rook AH, Vowels BR, Jaworsky C, Singh A, Lessin SR. The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sezary T cells. Arch Dermatol 1993;129:486–489.
   Google Scholar
• Showe LC, Fox FE, Williams D, Au K, Niu Z, Rook AH. Depressed IL-12-mediated signal transduction in T cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. J Immunol 1999;163:4073–4079.
   PubMed Web of Science ®Google Scholar
• Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992;99:90–94.
   PubMed Web of Science ®Google Scholar
• Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994;103:669–673.
   PubMed Web of Science ®Google Scholar
• Nebozhyn M, Loboda A, Kari L, et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 2006;107: 3189–3196.
   PubMedGoogle Scholar
• Wysocka M, Zaki MH, French LE, et al. Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 2002;100:3287–3294.
   PubMed Web of Science ®Google Scholar
• Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner LJ, Rook AH. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 2004;104:4142–4149.
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Yawalkar N, Jones DA, et al. Decreased T-cell receptor excision circles in cutaneous T-cell lymphoma. Clin Cancer Res 2005;11:5748–5755.
   PubMed Web of Science ®Google Scholar
• Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003;102:4059–4066.
   PubMed Web of Science ®Google Scholar
• Wood GS. Lymphocyte activation in cutaneous T-cell lymphoma. J Invest Dermatol 1995;105(1 Suppl.):105S–109S.
   PubMed Web of Science ®Google Scholar
• Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94:902–908.
   PubMed Web of Science ®Google Scholar
• Richardson SK, Lin JH, Vittorio CC, et al. High clinical response rate with multimodality immunomodulatory therapy for Sezary syndrome. Clin Lymphoma Myeloma 2006;7:226–232.
   PubMedGoogle Scholar
• Rook AH, Junkins-Hopkins JM, McGinnis KS, et al. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. Adv Dermatol 2002;18:29–43.
   PubMedGoogle Scholar
• Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 2009;21:131–137.
   PubMed Web of Science ®Google Scholar
• Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003;17:1435–1448, ix.
   PubMed Web of Science ®Google Scholar
• Ito T, Amakawa R, Kaisho T, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002;195:1507–1512.
   PubMed Web of Science ®Google Scholar
• Wysocka M, Newton S, Benoit BM, et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma 2007;7:524–534.
   PubMedGoogle Scholar
• Murphy GF. Cutaneous T-cell lymphoma. Adv Pathol 1988;1:131–156.
   Google Scholar
• Rook AH, Kubin M, Cassin M, et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995;154:1491–1498.
   PubMed Web of Science ®Google Scholar
• Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005;174:1259–1268.
   PubMed Web of Science ®Google Scholar
• Showe MK, Vachani A, Kossenkov AV, et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009;69:9202–9210.
   PubMed Web of Science ®Google Scholar
• Abbas AR, Baldwin D, Ma Y, et al. Immune Response In Silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun 2005;6:319–331.
   PubMed Web of Science ®Google Scholar
• Abrams JT, Lessin S, Ghosh SK, et al. A clonal CD4-positive T-cell line established from the blood of a patient with Sezary syndrome. J Invest Dermatol 1991;96:31–37.
   PubMed Web of Science ®Google Scholar
• Kawai T, Sato S, Ishii KJ, et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004;5:1061–1068.
   PubMed Web of Science ®Google Scholar
• Tsujimura H, Tamura T, Ozato K. Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells. J Immunol 2003;170:1131–1135.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545–15550.
   PubMed Web of Science ®Google Scholar
• Bouaziz JD, Ortonne N, Giustiniani J, et al. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in Sezary syndrome patients. J Invest Dermatol 2005;125:1273–1278.
   PubMed Web of Science ®Google Scholar
• Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6:769–776.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83–243.
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000;192:219–226.
   PubMed Web of Science ®Google Scholar
• Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424:516–523.
   PubMed Web of Science ®Google Scholar
• Hermann P, Rubio M, Nakajima T, Delespesse G, Sarfati M. IFN-alpha priming of human monocytes differentially regulates gram-positive and gram-negative bacteria-induced IL-10 release and selectively enhances IL-12p70, CD80, and MHC class I expression. J Immunol 1998;161:2011–2018.
   PubMed Web of Science ®Google Scholar
• D’Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041–1048.
   PubMed Web of Science ®Google Scholar
• Hayes MP, Wang J, Norcross MA. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 1995;86:646–650.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Airan LE, Uyemura K, et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. J Clin Invest 1997;99:336–341.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Villarino A, Artis D, Scott P. The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol Rev 2004;202:106–114.
   PubMed Web of Science ®Google Scholar
• Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221–242.
   PubMed Web of Science ®Google Scholar
• Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006;6:644–658.
   PubMed Web of Science ®Google Scholar
• Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine 2003;24:81–90.
   PubMed Web of Science ®Google Scholar
• Liu J, Guan X, Tamura T, Ozato K, Ma X. Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein. J Biol Chem 2004;279:55609–55617.
   PubMed Web of Science ®Google Scholar
• Politis AD, Ozato K, Coligan JE, Vogel SN. Regulation of IFN-gamma-induced nuclear expression of IFN consensus sequence binding protein in murine peritoneal macrophages. J Immunol 1994;152:2270–2278.
   PubMed Web of Science ®Google Scholar
• Bachem A, Guttler S, Hartung E, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+ CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010;207:1273–1281.
   PubMed Web of Science ®Google Scholar
• Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002;138:1137–1139.
   PubMed Web of Science ®Google Scholar
• Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005;97:1143–1153.
   PubMed Web of Science ®Google Scholar
• Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 2005;44:14–19.
   PubMed Web of Science ®Google Scholar
• Huber MA, Staib G, Pehamberger H, Scharffetter-Kochanek K. Management of refractory early-stage cutaneous T-cell lymphoma. Am J Clin Dermatol 2006;7:155–169.
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez MC, Verea-Hernando MM, Yebra-Pimentel MT, Del Pozo J, Mazaira M, Fonseca E. Imiquimod in mycosis fungoides. Eur J Dermatol 2008;18: 148–152.
   PubMed Web of Science ®Google Scholar
• Kim YH, Girardi M, Duvic M, et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010;63:975–983.
   PubMed Web of Science ®Google Scholar